Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
89,600,000
-
Total 13F shares
-
4,387,437
-
Share change
-
-25,870
-
Total reported value
-
$58,179,765
-
Put/Call ratio
-
89%
-
Price per share
-
$13.28
-
Number of holders
-
17
-
Value change
-
-$559,758
-
Number of buys
-
9
-
Number of sells
-
22
Institutional Holders of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) as of Q1 2024
As of 31 Mar 2024,
Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) was held by
17 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,387,437 shares.
The largest 10 holders included
JPMORGAN CHASE & CO, CITADEL ADVISORS LLC, MORGAN STANLEY, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, Bank of New York Mellon Corp, Legal & General Group Plc, DEUTSCHE BANK AG\, NEW YORK STATE COMMON RETIREMENT FUND, Voya Investment Management LLC, and Royal Bank of Canada.
This page lists
18
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.